



UBS LIFE SCIENCES INVESTOR CONFERENCE FEATURES ANGIOBLAST

New York, USA; 25 September 2008: Angioblast Systems Inc. was featured at the 2008 UBS Global Life Sciences Conference underway in New York.

Company founder Professor Silviu Itescu briefed international investors on the significant progress of Angioblast's clinical programs, including its ongoing Phase 2 trials for heart failure and heart attacks, plans to commence trials in vascular eye disorders such as diabetic retinopathy and macular degeneration, and new clinical directions in bone marrow transplantation.

Professor Itescu stated that this latest clinical opportunity may provide a fast-track path to early product commercialization following the company's recent success in obtaining orphan drug designation to use its proprietary stem cells in cancer patients needing bone marrow transplantation.

The eighth annual UBS Global Life Sciences Conference is among the largest healthcare investor conferences in the world with around 3,500 attendees.

About Angioblast Systems, Inc.

Angioblast Systems, Inc. is a private New York City based biotechnology company committed to the development of novel treatments for cardiac, vascular, and eye conditions. Angioblast's lead products are based on commercialization of a unique adult stem cell technology capable of regulating blood vessel growth critical for the treatment of ischemic heart disease and macular degeneration/diabetic eye disease. Our focus is to progress through clinical trials and regulatory processes necessary to commercialize the technology in as short a timeframe as possible.

Angioblast has the worldwide assignment of rights for a series of patents and technologies that have been developed over more than 10 years and which relate to the identification, extraction, culture expansion and enablement of adult Mesenchymal Precursor Cells (MPCs). Angioblast's strategy is to maximize shareholder value through both corporate partnerships and the rapid and successful completion of clinical milestones.

For further information please contact

Michael Schuster, MS, MBA
Vice President of Operations
T: (212) 880-2060
E: michael.schuster@angioblast.com
W: www.angioblast.com